This course on Thyroid Eye Disease (TED) offers comprehensive insights into diagnosing TED, including understanding its prevalence, impact, and the key signs and symptoms associated with ocular pathologies, as well as a detailed examination process. It further delves into the treatment modalities, focusing on the role of IGF-1R in TED's pathogenesis and the use of teprotumumab, while also distinguishing TED from ocular surface disease (OSD), and culminates with strategies for effective patient discussions.
This activity, COPE Activity Number 120866, is accredited by COPE for continuing education for optometrists.
COPE Course No.: 90122-SD
Release Date: 03-29-2024
Expiration Date: 03-28-2025
Grant Support Statement
This activity is supported by unrestricted educational grants from Alcon, Horizon Therapeutics, SightSciences, and Tarsus Pharmaceuticals, Inc.
Marc Bloomenstein, OD, FAAO
Director of Optometric Services
Doug Devries, OD
Director and Managing Partner